Opinion|Videos|April 21, 2025
Looking Into the Future and at Unmet Needs in EGFRm NSCLC
Panelists discuss how medical professionals identify key unmet needs in EGFR-mutated non–small cell lung cancer (NSCLC) treatment, particularly in overcoming resistance. Challenges include addressing acquired resistance to targeted therapies, enhancing central nervous system penetration, managing toxicity, and developing novel agents or combinations to improve long-term outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
What do you see as the biggest unmet needs in EGFR-mutated NSCLC treatment, particularly in the resistance setting?
Advertisement
Related to this article
A dual antigen–targeted T-cell engager doublet produced durable PSA responses in late-line metastatic castration-resistant prostate cancer.
Invikafusp alfa plus sacituzumab govitecan produced responses and disease control in metastatic TNBC and HR-positive/HER2-negative breast cancer.
The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
A post hoc analysis of SPEARHEAD-1 found that MAGE-A4 H-score was independently tied to response and progression-free survival, whereas baseline tumor burden was tied to overall survival.
The IL-12–expressing self-replicating mRNA STX-001 showed a favorable therapeutic window at 100 µg, with regression in both injected and non-injected lesions.
Most of the survival time accrued with RP1 plus nivolumab in the IGNYTE trial was spent in good health among patients with advanced melanoma after anti–PD-1 therapy.
VET3-TGI produced responses in injected and non-injected lesions without dose-limiting toxicities in the phase 1/1b STEALTH-001 trial.
IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.
Advertisement
Advertisement
Trending on OncLive
1
RP1 Plus Nivolumab Preserves Quality-Adjusted Survival in Advanced Melanoma After Anti–PD-1 Therapy
2
Afami-Cel Outcomes Are Tied to MAGE-A4 Expression, Tumor Burden in Synovial Sarcoma
3
STX-001 Produces Durable Systemic Responses in PD-1–Resistant Melanoma
4
VET3-TGI Generates Responses in Checkpoint Inhibitor–Refractory Cutaneous Cancers
5